Helius Medical Tech Azioni (NASDAQ: HSDT)

Ultime notizie per Helius Medical Tech (NASDAQ:HSDT) Azioni

Helius Medical Tech

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Technologies Inc

Helius Medical Technologies Inc Warrants (02/02/2026)

<p>Truist Securities  analyst David Macdonald   maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $175 to $190.</p>


News

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $190

<p>JP Morgan  analyst Brian Essex   maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and lowers the price target from $36 to $29.</p>


JP Morgan Maintains Neutral on Rapid7, Lowers Price Target to $29

WIIM

Evercore shares are trading higher after Keefe, Bruyette & Woods raised its price target on the stock from $238 to $257.

<p>Truist Securities  analyst David Macdonald   maintains Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) with a Hold and raises the price target from $28 to $32.</p>


PNTG

Truist Securities Maintains Hold on Pennant Gr, Raises Price Target to $32

<p>Truist Securities  analyst David Macdonald   maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $274 to $290.</p>


Laboratory Corporation Of America Holdings

Truist Securities Maintains Buy on Labcorp Hldgs, Raises Price Target to $290

<p>JP Morgan  analyst Brian Essex   maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Overweight and lowers the price target from $29 to $25.</p>


CLBT

JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $25

<p>Truist Securities  analyst David Macdonald   maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $325 to $305.</p>


Truist Securities Maintains Hold on Humana, Lowers Price Target to $305

GRFS

Grifols shares are trading higher after the company provided Q1 financial results.

<p><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has posted a 27% gain over the past week, with traders now expecting a much larger breakout. Despite a slight dip in whale activity, retail interest appears to be rising as Shibarium adoption continues <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">and tokenomics improve.</a></p>
<p><figure class="wp-block-table"><br />
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>24-Hour Trend</strong></td>
<td><strong>7-Day Trend</strong></td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001610</td>
<td>$9.5 billion</td>
<td>+1.6%&nbsp;</td>
<td>&nbsp;+26.6%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2342</td>
<td>$34.95 billion</td>
<td>&nbsp;+2.3%</td>
<td>&nbsp;+37%</td>
</tr>
<tr>
<td><strong>Pepe</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001383</td>
<td>$5.8 billion</td>
<td>+2.7%&nbsp;</td>
<td>+74.5%&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>Crypto trader CW sees Shiba Inu trying to break through the sell wall. If it breaks through, the next one is at $0.0000224.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> is trying to break through the sell wall.<br /><br />If it breaks through the current sell wall, the next one is $0.0000224. <a href="https://t.co/pg7EwRD8uo">pic.twitter.com/pg7EwRD8uo</a></p>
<p>&mdash; CW (@CW8900) <a href="https://twitter.com/CW8900/status/1921804434994020657?ref_src=twsrc%5Etfw">May 12, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>According to Coinpedia Markets, SHIB <a href="https://x.com/MarketCoinpedia/status/1921884391242133573">outperformed</a> even high-flying tokens like TRUMP, despite major news events tied to the latter. SHIB is now trading above all major daily and weekly moving averages, with the RSI holding firm at 71, a sign of ongoing strength.</p>
<p>If Shiba Inu breaks resistance at $0.00002148, analysts forecast a move toward $0.00003575, which would mark a 122% rally from recent levels. The price action is also said to mirror the coin's September 2024 breakout setup, further supporting bullish expectations.</p>
<p><strong>Statistics: </strong>On-chain growth from Shibarium, including rising accounts, transactions, and new integrations like Zypto, plus Bury 2.0 incentives, are boosting utility and long-term adoption. </p>
<p>Shibarium, Shiba Inu's Layer-2 scaling solution, is showing strong growth across the board: accounts grew from 240,421 (March 1) to 268,877 (May 10), transactions increased from 931 million to 1.15 billion. </p>
<p>New integrations such as Zypto and Bury 2.0 are helping drive long-term utility and ecosystem stickiness.</p>
<p>Shibburn data shows the burn rate increasing by 2,267.9% in the past 24 hours, with 13.69 million SHIB burned. A single transaction burned 13.69 million SHIB around seven hours ago.</p>
<p>IntoTheBlock data shows Shiba Inu large transaction volume down by 29.8% in a single day, while daily active addresses were up 0.95%. Transactions greater than $100,000 dropped from 161 to 115 in a single day.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally">Scottie Pippen Declares &#8216;Altcoin Season&#8217; As Ethereum, XRP, Dogecoin, Shiba Inu Rally</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Jumps 27% In 7 Days: What Is Going On?

<p>Truist Securities  analyst David Macdonald   maintains Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) with a Hold and raises the price target from $25 to $30.</p>


Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $30

<p>JP Morgan  analyst Richard Shane   maintains Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) with a Overweight and raises the price target from $19 to $19.5.</p>


STWD

JP Morgan Maintains Overweight on Starwood Property Trust, Raises Price Target to $19.5

<p>Truist Securities  analyst David Macdonald   maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $82 to $84.</p>


Truist Securities Maintains Buy on CVS Health, Raises Price Target to $84

<p>Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $33.71, a high estimate of $42.00, and a low estimate of $28.00. Observing a downward trend, the current average is 5.6% lower than the prior average price target of $35.71. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747072883_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Warner Music Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Laszczyk</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Batya Levi</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Warner Music Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Warner Music Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Warner Music Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Warner Music Gr's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WMG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Warner Music Gr analyst ratings.</strong></a></p>
<h2>All You Need to Know About Warner Music Gr</h2>
<p>Warner Music is the third-largest of the three major record companies. Recorded music accounts for most of the firm's revenue, with the segment housing notable record labels including Atlantic Records, Warner Records, Elektra Records. Some of the most successful current artists signed to record deals with Warner include Ed Sheeran, Bruno Mars, Cardi B, and Dua Lipa. Warner's remaining revenue comes from its publishing business, where Warner Chappell represents more than 180,000 songwriters and composers, some of whom are also Warner recording artists but many of whom are not recording artists or are attached to other labels. Warner Chappell controls more than 1 million musical compositions. Access Industries controls 98% of Warner's voting rights, while holding a 72% economic interest.</p>
<h3>Financial Insights: Warner Music Gr</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Warner Music Gr's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-0.67%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.43%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Warner Music Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.47%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.38%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>8.03</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Warner Music Gr Stock

<p>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Exelixis will report an <strong>earnings per share</strong> (EPS) of $0.38.</p>
<p>The announcement from Exelixis is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.06 in the last quarter, leading to a 0.03% drop in the share price on the following day.</p>
<p>Here's a look at Exelixis's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.49</td>
<td>0.35</td>
<td>0.30</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.55</td>
<td>0.47</td>
<td>0.84</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>13.0%</td>
<td>13.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747072871_0.png" alt="eps graph" /></p>
<h3>Tracking Exelixis's Stock Performance</h3>
<p>Shares of Exelixis were trading at $36.17 as of May 09. Over the last 52-week period, shares are up 77.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Exelixis</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exelixis.</p>
<p>A total of 11 analyst ratings have been received for Exelixis, with the consensus rating being Buy. The average one-year price target stands at $37.82, suggesting a potential 4.56% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Exact Sciences, Moderna and Biomarin Pharmaceutical, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Exact Sciences, with an average 1-year price target of $63.92, suggesting a potential 76.72% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Moderna, with an average 1-year price target of $42.91, suggesting a potential 18.63% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Biomarin Pharmaceutical, with an average 1-year price target of $94.4, suggesting a potential 160.99% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>In the peer analysis summary, key metrics for Exact Sciences, Moderna and Biomarin Pharmaceutical are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>18.16%</td>
<td>$546.79M</td>
<td>6.19%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Outperform</td>
<td>10.86%</td>
<td>$500.55M</td>
<td>-4.22%</td>
</tr>
<tr>
<td>Moderna</td>
<td>Neutral</td>
<td>-35.93%</td>
<td>$17M</td>
<td>-9.26%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical</td>
<td>Neutral</td>
<td>14.84%</td>
<td>$593.59M</td>
<td>3.24%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Exelixis ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.</p>
<h3>Get to Know Exelixis Better</h3>
<p>Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.</p>
<h3>A Deep Dive into Exelixis's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Exelixis's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>18.16%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Exelixis's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>24.68%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.19%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.73%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.09</strong>.</p>
<p><a href="https://www.benzinga.com/quote/EXEL/earnings"><strong>To track all earnings releases for Exelixis visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

EXEL

Exploring Exelixis's Earnings Expectations

<p>High-rolling investors have positioned themselves bullish on Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in FTNT often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Fortinet. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 55% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $27,060, and 8 calls, totaling $666,934.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $135.0 for Fortinet, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Fortinet stands at 767.0, with a total volume reaching 522.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Fortinet, situated within the strike price corridor from $90.0 to $135.0, throughout the last 30 days.</p>
<h3>Fortinet Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747072872_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$100.00</td>
<td>$149.0K</td>
<td>7</td>
<td align="right">1</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$100.00</td>
<td>$149.0K</td>
<td>7</td>
<td align="right">1</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.2</td>
<td>$4.9</td>
<td>$5.2</td>
<td>$97.50</td>
<td>$104.0K</td>
<td>924</td>
<td align="right">202</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.0</td>
<td>$3.85</td>
<td>$4.0</td>
<td>$100.00</td>
<td>$79.6K</td>
<td>2.5K</td>
<td align="right">69</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$6.3</td>
<td>$5.6</td>
<td>$5.85</td>
<td>$95.00</td>
<td>$58.5K</td>
<td>162</td>
<td align="right">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Fortinet</h3>
<p>Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.</p>
<p>Having examined the options trading patterns of Fortinet, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Fortinet Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,224,225, with FTNT's price up by 3.71%, positioned at $101.03.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 85 days.</li>
</ul>
<h3>Professional Analyst Ratings for Fortinet</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $105.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Neutral rating on Fortinet with a target price of $100.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Fortinet, which currently sits at a price target of $105.<br />
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Outperform rating on Fortinet, which currently sits at a price target of $115.<br />
&#x2A; An analyst from Roth Capital downgraded its action to Neutral with a price target of $103.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Fortinet, targeting a price of $105. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Fortinet, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

FTNT

Unpacking the Latest Options Trading Trends in Fortinet

<p>14 analysts have expressed a variety of opinions on Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $79.57, with a high estimate of $88.00 and a low estimate of $70.00. This current average represents a 13.04% decrease from the previous average price target of $91.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747072869_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Sempra among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ryan Levine</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$77.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$72.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Carly Davenport</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Anthony Crowdell</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shahriar Pourreza</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Daniel Ford</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sempra. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sempra compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Sempra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sempra's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sempra analyst ratings.</strong></a></p>
<h2>Get to Know Sempra Better</h2>
<p>Sempra Energy serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. SoCalGas and San Diego Gas &amp; Electric distribute gas to more than 20 million customers, while Oncor serves more than 10 million Texas customers. Sempra Infrastructure partners, of which Sempra holds a controlling ownership, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.</p>
<h3>Sempra: A Financial Overview</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Sempra's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>4.45%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.</p>
<p><strong>Net Margin:</strong> Sempra's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>23.83%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sempra's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>2.97%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Sempra's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.93%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.23</strong>, Sempra adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Sempra In The Eyes Of 14 Experts

<p>High-rolling investors have positioned themselves bearish on Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in COHR often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Coherent. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 11% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $94,500, and 8 calls, totaling $580,331.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $67.0 to $100.0 for Coherent over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Coherent's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Coherent's substantial trades, within a strike price spectrum from $67.0 to $100.0 over the preceding 30 days.</p>
<h3>Coherent Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747072867_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$2.85</td>
<td>$2.25</td>
<td>$2.6</td>
<td>$75.00</td>
<td>$265.0K</td>
<td>4.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>COHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$18.9</td>
<td>$18.8</td>
<td>$18.9</td>
<td>$85.00</td>
<td>$94.4K</td>
<td>1.1K</td>
<td>64</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$8.2</td>
<td>$6.9</td>
<td>$7.57</td>
<td>$70.00</td>
<td>$75.7K</td>
<td>1.1K</td>
<td>216</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.7</td>
<td>$7.4</td>
<td>$7.35</td>
<td>$70.00</td>
<td>$73.5K</td>
<td>1.1K</td>
<td>115</td>
</tr>
<tr>
<td>COHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$10.3</td>
<td>$9.1</td>
<td>$9.44</td>
<td>$67.00</td>
<td>$44.6K</td>
<td>87</td>
<td>51</td>
</tr>
</tbody>
</table>
</p>
<h3>About Coherent</h3>
<p>Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.</p>
<p>After a thorough review of the options trading surrounding Coherent, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Coherent's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,891,964, the COHR's price is up by 7.69%, now at $76.0. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 94 days.</li>
</ul>
<h3>What The Experts Say On Coherent</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $90.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Coherent with a target price of $110.<br />
&#x2A; Maintaining their stance, an analyst from Rosenblatt continues to hold a Buy rating for Coherent, targeting a price of $95.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $85.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Coherent with a target price of $80.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Coherent with a target price of $80. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Coherent options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


COHR

Unpacking the Latest Options Trading Trends in Coherent

<p>Truist Securities  analyst David Macdonald   maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $385 to $405.</p>


Truist Securities Maintains Buy on Cigna Group, Raises Price Target to $405

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Broadcom</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AVGO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 92 uncommon options trades for Broadcom.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 47% bullish and 45%, bearish.</p>
<p>Out of all of the special options we uncovered, 14 are puts, for a total amount of $595,447, and 78 are calls, for a total amount of $7,589,592.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $370.0 for Broadcom during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Broadcom stands at 3286.0, with a total volume reaching 40,947.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Broadcom, situated within the strike price corridor from $100.0 to $370.0, throughout the last 30 days.</p>
<h3>Broadcom Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747072861_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$64.05</td>
<td>$63.4</td>
<td>$63.4</td>
<td>$210.00</td>
<td>$951.0K</td>
<td>111</td>
<td>1.7K</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$18.5</td>
<td>$18.3</td>
<td>$18.44</td>
<td>$200.00</td>
<td>$946.7K</td>
<td>10.0K</td>
<td>768</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.2</td>
<td>$13.05</td>
<td>$13.12</td>
<td>$220.00</td>
<td>$813.5K</td>
<td>9.6K</td>
<td>2.1K</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.2</td>
<td>$8.05</td>
<td>$8.05</td>
<td>$250.00</td>
<td>$806.5K</td>
<td>3.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$57.0</td>
<td>$56.8</td>
<td>$57.0</td>
<td>$210.00</td>
<td>$171.0K</td>
<td>930</td>
<td>61</td>
</tr>
</tbody>
</table>
</p>
<h3>About Broadcom</h3>
<p>Broadcom is the sixth-largest semiconductor company globally and has expanded into various software businesses, with over $30 billion in annual revenue. It sells 17 core semiconductor product lines across wireless, networking, broadband, storage, and industrial markets. It is primarily a fabless designer but holds some manufacturing in-house, like for its best-of-breed FBAR filters that sell into the Apple iPhone. In software, it sells virtualization, infrastructure, and security software to large enterprises, financial institutions, and governments.Broadcom is the product of consolidation. Its businesses are an amalgamation of former companies like legacy Broadcom and Avago Technologies in chips, as well as Brocade, CA Technologies, and Symantec in software.</p>
<p>In light of the recent options history for Broadcom, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Broadcom's Current Market Status</h3>
<ul>
<li>With a trading volume of 12,489,711, the price of AVGO is up by 5.22%, reaching $219.07.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 24 days from now.</li>
</ul>
<h3>What The Experts Say On Broadcom</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $228.33.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Broadcom, which currently sits at a price target of $240.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Broadcom, which currently sits at a price target of $215.<br />
&#x2A; An analyst from Seaport Global has revised its rating downward to Buy, adjusting the price target to $230. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Broadcom, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AVGO

Check Out What Whales Are Doing With AVGO

<p>4 analysts have shared their evaluations of PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $83.75, with a high estimate of $90.00 and a low estimate of $65.00. This upward trend is evident, with the current average reflecting a 2.45% increase from the previous average price target of $81.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747072859_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive PAR Technology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to PAR Technology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PAR Technology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of PAR Technology's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PAR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on PAR Technology analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind PAR Technology</h2>
<p>PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.</p>
<h3>PAR Technology: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining PAR Technology's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>50.22%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> PAR Technology's net margin excels beyond industry benchmarks, reaching <strong>-20.05%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> PAR Technology's ROE excels beyond industry benchmarks, reaching <strong>-2.69%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> PAR Technology's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-1.57%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.43</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


4 Analysts Have This To Say About PAR Technology

Press Releases

General

Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

Health Care

Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System

Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target

Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study

Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device

Comments

Helius Medical Tech

Notizie

Ultime notizie per Helius Medical Tech (NASDAQ:HSDT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO